Sopharma AD Third Quarter 2023 Earnings: EPS: лв0.12 (vs лв0.20 in 3Q 2022)
Sopharma AD (BUL:SFA) Third Quarter 2023 Results
Key Financial Results
- Revenue: лв465.9m (up 12% from 3Q 2022).
- Net income: лв14.3m (down 42% from 3Q 2022).
- Profit margin: 3.1% (down from 5.9% in 3Q 2022). The decrease in margin was driven by higher expenses.
- EPS: лв0.12 (down from лв0.20 in 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sopharma AD shares are down 1.4% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 4 warning signs for Sopharma AD you should be aware of, and 1 of them can't be ignored.
If you're looking to trade Sopharma AD, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BUL:SFA
Sopharma AD
Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally.
Flawless balance sheet second-rate dividend payer.
Similar Companies
Market Insights
Community Narratives

